MT-CO1 and anaphylaxis: The second comes from being based on a still limited number of hypersensitive patients (20/332 for model 1 and 17/332 for model 2) in whom we could not systematically confirm that the identified NSAID or other COXi actually caused the (reported) DHR through diagnostic drug challenges, due to unfavorable risk/benefit analysis (high frequency of anaphylaxis) or refusal by patients.